Latest News about RHHBY
Recent news which mentions RHHBY
Poseida Therapeutics' New Treatment For Multiple Myeloma Shows Early Success In Clinical Trial
December 11, 2023
From Benzinga
Why Viking Therapeutics Was Crushing It This Week
December 08, 2023
From Motley Fool
From MarketWatch
JNJ CEO Signals No Rush Into Weight-Loss Drug Realm, Emphasizes Different Priorities
December 06, 2023
From Benzinga
While Pfizer Faced A Setback, Altimmune, Roche And Mainz Biomed Advanced in The Battle Against Obesity And Colorectal Cancer
December 05, 2023
From Benzinga
Roche's Combination Therapy Shows Improved Progression Free Survival In Certain Breast Cancer With Mutation
December 05, 2023
From Benzinga
Jim Cramer Highlights 'Transformational' Impact Of Weight Loss Drugs Like Ozempic: Focus Now On 'Potential Winners' From The Same Narrative
December 04, 2023
From Benzinga
From Benzinga
AstraZeneca Strikes Deal With Absci To Leverage AI In Cancer Drug Discovery: Report
December 04, 2023
From Benzinga
Ignore Crypto: These Stocks Could Make You Rich
November 23, 2023
From Motley Fool
Biotech Breakthroughs: 3 Revolutionary Stocks Redefining Healthcare
November 17, 2023
From InvestorPlace
FDA Approves Bristol-Myers' Lung Cancer Drug Acquired Via $4B Turning Point Deal: Competes With Roche, Merck, AstraZeneca
November 16, 2023
From Benzinga
The Alzheimer's Drug Market Is Heating Up. Should You Buy the Leading Contenders' Stocks?
November 10, 2023
From Motley Fool
Regeneron's Skin Drugs Propel Revenue In Q3, Witnesses Strong Demand For Higher Dose Version Of Flagship Eye Drug
November 02, 2023
From Benzinga
Sarepta/Roche's Closely Watched Duchenne Gene Therapy Faces More FDA Scrutiny - Stock Tanks
October 31, 2023
From Benzinga
Are Your Eyes At Grave Risk? FDA Issues Dangerous Warning Over Popular Drops From CVS, Target, Cardinal Health And More
October 28, 2023
From Benzinga
Roche, Lilly or Pfizer: Who's the Winner in IBD Wars?
October 28, 2023
From Motley Fool
From Motley Fool
Why Is Roivant Sciences (ROIV) Stock Up Today?
October 23, 2023
From InvestorPlace
Roche Buys Pfizer & Roivant Sciences' Televant In ~$7.1B Deal
October 23, 2023
From Benzinga
Roivant, Pfizer shares rise as Roche agrees to buy immunology company for $7.1 billion
October 23, 2023
From MarketWatch
Which Is the Better Long-Term Hold for Investors: Pfizer or Roche?
October 21, 2023
From Motley Fool
From MarketWatch
From Benzinga
What's Going On Cancer Player Monte Rosa Therapeutics Stock Today?
October 17, 2023
From Benzinga
FDA Approves Merck's Top Selling Drug, Keytruda For Expanded Use In Lung Cancer Indication
October 17, 2023
From Benzinga
Why Is Alzheimer's Player Prothena Stock Trading Higher Today?
October 16, 2023
From Benzinga
Tempest Therapeutics shares head back to earth after 4,000% gain
October 12, 2023
From MarketWatch
TPST Stock: 7 Things to Know About Tempest Therapeutics
October 11, 2023
From InvestorPlace
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
